Par Claims Rival Misled Patients With Nasal Spray

Law360, New York (May 20, 2009, 12:00 AM EDT) -- Par Pharmaceuticals Inc. has filed suit against Fleming & Co. Pharmaceuticals, claiming the rival drug company infringed its patent and intentionally misled consumers with the marketing of its prescription nasal spray, CaloMist.

Par filed an amended complaint in the U.S. District Court for the Southern District of California on Tuesday, accusing Fleming of patent infringement, violations of the Lanham Act and unfair competition under state law.

Both CaloMist and Par's Nascobal product are prescription nasal sprays used as an alternative to monthly injections to treat vitamin...
To view the full article, register now.